Not Approved
This substance is not approved by any major regulatory body for human therapeutic use. All information is derived from preclinical research, limited clinical studies, or off-label contexts.
Evidence Gaps
Significant evidence gaps exist for this substance. Available literature is heterogeneous, independently unreplicated, or relies heavily on secondary synthesis. Claims should be treated as exploratory hypotheses.
Evidence visual
Epitalon evidence and risk matrix
advanced researcher fit
Evidence
Tier C-D
Risk
high
Regulatory
not approved
WADA
none
FDA
unknown
Route
subcutaneous
Mixed evidence profile. Useful for comparison, not a standalone protocol decision.
Overview
Epitalon is a tetrapeptide frequently described as influencing melatonin/circadian biology and telomerase-related pathways, but evidence quality is heterogeneous and independent replication is limited. Secondary synthesis suggests intranasal 10-30 mg/day for 20-30 days and intramuscular 5-10 mg/day for 10-20 days, with periodic courses. Sparse modern safety datasets; high uncertainty.
Decision path
Where Epitalon fits in the research path.
Use the evidence and risk profile first, then compare vendors and run the quiz before turning this compound into a protocol decision.
01
Read evidence
02
Check risk
03
Compare options
04
Build plan
Peptide research path
Decide whether Epitalon belongs in your plan.
Use the quiz before choosing a compound, vendor, or PDF. It routes by goal, experience, budget, safety flags, and monitoring comfort.
Research Details
Proposed influence on melatonin/circadian biology and telomerase-related pathways; evidence quality heterogeneous.
subcutaneous, intramuscular, intranasal
Secondary synthesis: intranasal 10-30 mg/day (20-30 days); IM 5-10 mg/day (10-20 days).
Longevity/circadian claims; telomerase association not established as fact.
Often marketed as weeks-long courses; treat as hypothesis.
No established data.
Sparse modern safety datasets; high uncertainty.
Unknown.
Cost at a glance
Typical cycle cost
$59.98
Estimated monthly
$79.97
Protocol style
10-20 day burst
Short burst
Estimate confidence
High confidence
Assumes roughly 10 mg–20 mg per cycle, using 1 tracked affiliated listing.
Reflects short Russian-style anti-aging bursts rather than ongoing use.
Age, sex, and monitoring
Life-stage fit
Usually discussed in older-adult longevity and sleep-maintenance contexts, not younger performance use.
Best fit age ranges: 45-54, 55-64, 65+
Information provided for educational and research reference only. Not medical advice. Not for diagnosing, treating, curing, or preventing disease. Products referenced are labeled Research Use Only (RUO) by vendors; not for human or veterinary use.
Sources and review notes
- Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks - U.S. Food and Drug Administration - accessed 2026-05-15
Used for FDA compounding-risk context and peptide safety flags.
- The Prohibited List - World Anti-Doping Agency - accessed 2026-05-15
Used for athlete-facing WADA risk and peptide-class restrictions.
- Peptide therapeutics: current status and future directions - PubMed / Nature Reviews Drug Discovery - accessed 2026-05-15
Used for broad peptide-therapeutics background and evidence framing.
Personalized peptide routing
Find the right path for Epitalon.
Take the quiz before choosing a compound, vendor, or PDF. We match your goal, experience, budget, and monitoring comfort to the next best step in the funnel.
- Goal-matched compound and protocol recommendations.
- Budget and sourcing filters before you leave the site.
- PDF unlocks shown after your personalized result.